EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia

Ngula Monde, Musso Munyeme iD, Gershom Chongwe iD, Jonas Johansson Wensman, Mildred Zulu iD, Seter Siziya iD, Rabecca Tembo, Kabengele K Siame, Obi Shambaba, Sydney Malama

Antibiotics · 12.01.2023 · 12 (1) · 166

DOI: 10.3390/antibiotics12010166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibiotics, online erschienen am 12.01.2023. Verfasst von Ngula Monde und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Tropical Diseases Research Center, Ndola P.O. Box 71769, Zambia. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: African Centre for Infectious Diseases in Humans and Animals, World Bank.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Drug-resistant tuberculosis has continued to be a serious global health threat defined by complexity as well as higher morbidity and mortality wherever it occurs, Zambia included. However, the paucity of information on drug-susceptibility patterns of both first-line and second-line anti-tuberculosis (anti-TB) drugs, including the new and repurposed drugs used in the management of drug-resistant tuberculosis in Zambia, was the major thrust for conducting this study.

Methods

A total of 132 bacteriologically confirmed TB isolates were collected from patients with pulmonary TB during the period from April 2020 to December 2021 in Southern and Eastern Provinces of Zambia. Drug-resistance profiles were determined according to four first-line and five second-line anti-TB drugs. Standard mycobacteriological methods were used to isolate and determine phenotypic drug susceptibility. Data on the participants’ social–demographic characteristics were obtained using a pre-test checklist.

Results

Overall, the prevalence of resistance to one or more anti-TB drugs was 23.5% (31/132, 95% CI: 16.5–31.6%). A total of 9.8% (13/132, 95% CI: 5.3–16.2%) of the patients had multidrug-resistant TB and 1.2% were new cases, while 25.5% had a history of being previously treated for TB. Among those with mono-resistant TB strains, isoniazid (INH) resistance was the highest at 9.8% (13/132, 95% CI: 5.3–16.2%). Two (2/31) (6.5%) XDR-TB and one (1/31) (3.2%) pre-XDR-TB cases were identified among the MDR-TB patients. Previously treated patients were 40 times more likely (OR; 40.3, 95% CI: 11.1–146.5%) to have drug-resistant TB than those who had no history of being treated for TB.

Conclusion

This study has established a high rate of multidrug-resistant TB and has further identified both pre-XDR- and XDR-TB. There is a need to intensify surveillance of MDR- and XDR-TB to inform future guidelines for effective treatment and monitoring.

Schlagwörter

Stichwörter der Autor:innen

drug resistanceextensively drug-resistantmultidrugsecond-line drugstuberculosis

Autor:innen und Institutionen

  • Department of Biomedical Sciences, Tropical Diseases Research Center, Ndola P.O. Box 71769, Zambia.
  • Department of Disease Control, School of Veterinary Medicine, University of Zambia, Lusaka P.O. Box 32379, Zambia.
  • Department of Clinical Sciences, Swedish University of Agricultural Sciences, 750 07 Uppsala, Sweden.
  • Department of Disease Control and Epidemiology, National Veterinary Institute, 751 89 Uppsala, Sweden.
  • Department of Pathology and Microbiology, School of Medicine, University of Zambia, Lusaka P.O. Box 50110, Zambia.
  • Department of Public Health, Michael Chilufya Sata School of Medicine, Copperbelt University, Ndola P.O. Box 71191, Zambia.

ORCID-Profile: Musso Munyeme, Gershom Chongwe, Mildred Zulu, Seter Siziya

Förderung

  • African Centre for Infectious Diseases in Humans and Animals
  • World Bank

Zitieren

APA

Monde, N., Munyeme, M., Chongwe, G., Wensman, J. J., Zulu, M., Siziya, S., Tembo, R., Siame, K. K., Shambaba, O., & Malama, S. (2023). First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia. Antibiotics, 12(1), 166. https://doi.org/10.3390/antibiotics12010166

Vancouver

Monde N, Munyeme M, Chongwe G, Wensman JJ, Zulu M, Siziya S, et al. First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia. Antibiotics. 2023;12(1):166. doi:10.3390/antibiotics12010166

BibTeX
@article{Monde2023,
  author = {Monde, Ngula and Munyeme, Musso and Chongwe, Gershom and Wensman, Jonas Johansson and Zulu, Mildred and Siziya, Seter and Tembo, Rabecca and Siame, Kabengele K and Shambaba, Obi and Malama, Sydney},
  title = {First and Second-Line Anti-Tuberculosis Drug-Resistance Patterns in Pulmonary Tuberculosis Patients in Zambia},
  journal = {Antibiotics},
  year = {2023},
  volume = {12},
  number = {1},
  pages = {166},
  doi = {10.3390/antibiotics12010166}
}
Kostenlos starten →